NEW YORK & MAINZ, Germany, October 26, 2021--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 17 to 0, with 1 abstention, to recommend the FDA grant Emergency Use Authorization (EUA) for the companies’ COVID-19 vaccine in children 5 to <12 years of age. VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters,
BioNTech signs Memorandum of Understanding with Rwandan Government and the Institut Pasteur de Dakar. Construction of the first mRNA manufacturing facility in Africa is planned to be initiated in mid-2022First manufacturing facility will become a node in a decentralized and robust African end-to-end manufacturing network Development and implementation of a scalable regional manufacturing network to enable an annual manufacturing capacity of several hundreds of million mRNA vaccine doses MAINZ, G
Last week, the U.S. Food and Drug Administration (FDA) authorized the use of "mix-and-match" COVID-19 vaccine boosters. Any person eligible to receive a booster won't have to stick with the same vaccine used in their primary vaccination. This FDA decision opens the door to even more of a contest between the three COVID-19 vaccines currently available in the U.S. That's especially the case between the two most widely adopted vaccines.